Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In a double-blind Phase II trial in 157 patients, VEGF Trap-Eye significantly reduced baseline retinal thickness after 12
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury